Literature DB >> 9264001

Moxonidine inhibits Na+/H+ exchange in proximal tubule cells and cortical collecting duct.

E Schlatter1, I Ankorina-Stark, S Haxelmans, H Hohage.   

Abstract

The imidazoline receptor agonist moxonidine has been recently introduced as an antihypertensive therapy. Imidazoline specific binding sites have also been found in the kidney. Moxonidine induced natriuresis and diuresis in clearance studies in rats. Related substances such as various guanidinium derivatives have been shown to inhibit Na+/H+ exchange in several preparations. We therefore examined whether the renal effects of moxonidine could be mediated by an inhibition of the Na+/H+ exchanger. Intracellular pH (pHi) was measured microfluorimetrically with BCECF in proximal LLC-PK1 cells and in the principal cells of rat cortical collecting ducts (CCD). In LLC-PK1 cells moxonidine (10 mumol/liter) had no effect on the basal pH1; however, it reduced the Na+/H+ activity reversibly by 43 +/- 4% (N = 26) when the exchanger was activated by cellular acidification. In rat CCD cells moxonidine slightly decreased basal pHi by 0.08 +/- 0.03 pH units (N = 12). After acidification the recovery rate of pHi was reduced with moxonidine by 45 +/- 6% (N = 18). The effects of moxonidine could be mimicked in both cell types by inhibitors of the Na+/H+ exchanger (HOE 694, amiloride). In the presence of the imidazoline receptor antagonist idazoxan (10 mumol/liter) the effects of moxonidine were almost completely inhibited. The alpha 2-antagonist yohimbine (10 mumol/liter) did not significantly alter the effects of moxonidine in both cell types. These data suggest that in LLC-PK1 and in rat CCD cells, Na+/H+ is inhibited by moxonidine via an activation of the imidazoline receptor.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9264001     DOI: 10.1038/ki.1997.352

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  3 in total

Review 1.  Drugs acting on imidazoline receptors: a review of their pharmacology, their use in blood pressure control and their potential interest in cardioprotection.

Authors:  P Bousquet; J Feldman
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

2.  Urinary responses to acute moxonidine are inhibited by natriuretic peptide receptor antagonist.

Authors:  Rouwayda El-Ayoubi; Ahmed Menaouar; Jolanta Gutkowska; Suhayla Mukaddam-Daher
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

3.  Analgesic efficacy of CR4056, a novel imidazoline-2 receptor ligand, in rat models of inflammatory and neuropathic pain.

Authors:  Flora Ferrari; Simonetta Fiorentino; Laura Mennuni; Paolo Garofalo; Ornella Letari; Stefano Mandelli; Antonio Giordani; Marco Lanza; Gianfranco Caselli
Journal:  J Pain Res       Date:  2011-04-18       Impact factor: 3.133

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.